An observational study in Growth Hormone Treatment and Growth Disorders, sponsored by Beijing Children's Hospital. Recruiting at 1 site in China. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Beijing Children's Hospital · Observational
In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.
A database registration study was developed to retrospectively analyze the efficacy and safety of polyethylene glycol recombinant human growth hormone injection in the treatment of slow growth in children caused by endogenous growth hormone deficiency, idiopathic short stature, Turner syndrome, etc., and to further prospectively follow up and monitor. In order to participate in the global real-world use of long-acting growth hormone, all data from this study were uploaded to the Global Registry of New Therapies for Rare Endocrine Diseases and Bone Disorders (GloBE-Reg) platform.
167 studies on the registry are indexed under Growth Disorders; 24 are open to participants now.
This study's planned enrollment of 2,600 is above the median of 205 across 67 observational studies indexed under Growth Disorders.
Browse Growth Disorders studies →Beijing Children's Hospital is the lead sponsor of 51 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The height of the patients was below 2 stadard deviation below average. The patients were diagosesed as endogenous growth hormone deficiency, TS, SGA, ISS, etc. and treated with polyethylene glycol recombinant human growth hormone injection
Patients with endogenous growth hormone deficiency, Turner Syndrome, SGA, idiopathic short stature, etc. treated with polyethylene glycol recombinant human growth hormone injection
Exclusion Criteria:
Patients with serious heart and lung, blood system, malignant tumors and other diseases or systemic infections, immune function is low and Persons with mental illness;
Growth hormone deficiency (GHD) is a rare and treatable condition that causes short height in children and metabolic issues in adults.
Drug: Polyethylene glycol recombinant human growth hormone injection
Idiopathic short stature is a condition in which the height of the individual is more than 2 SD below the corresponding mean height for a given age, sex and population, in whom no identifiable disorder is present.
Drug: Polyethylene glycol recombinant human growth hormone injection
Small for gestational age (SGA) is defined as a birth weight of less than 10th percentile for gestational age.
Drug: Polyethylene glycol recombinant human growth hormone injection
Turner syndrome, a condition that affects only females, results when one of the X chromosomes (sex chromosomes) is missing or partially missing.
Drug: Polyethylene glycol recombinant human growth hormone injection
others who with the height of the individual is more than 2 SD below the corresponding mean height for a given age, sex and population.
Drug: Polyethylene glycol recombinant human growth hormone injection
0.1-0.3mg/kg.w
the change in height standard deviation score
final adult height standard deviation score- height standard deviation score before treatment
Time frame: 3-10years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Children's Hospital